SCM
LRMR icon

Stonepine Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Stonepine Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,000
Closed -$80.8K – 79
2025
Q3 		$80.8K Buy
+25,000
New +$93.7K 0.07% 55

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stonepine Capital Management's LRMR Position: Q4 2025 in Review

Stonepine Capital Management sold out of Larimar Therapeutics (LRMR) in Q4 2025, closing a stake of 25,000 shares — an estimated $80.8K sold.

Stonepine Capital Management first reported a position in LRMR in Q3 2025 and held it in 1 quarter. The position peaked at $80.8K in Q3 2025. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

  • Stonepine Capital Management reported no remaining Larimar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 25,000 Larimar Therapeutics shares in Q4 2025, an estimated $80.8K.
  • Stonepine Capital Management first reported a position in Larimar Therapeutics in Q3 2025 and held it in 1 quarter.
  • Stonepine Capital Management's Larimar Therapeutics position peaked at $80.8K in Q3 2025.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.